CytogeNiks is a UK-based biotech venture focused on developing affordable diagnostics to improve healthcare. Our main focus is on tackling the issues preventing the prompt diagnosis of sepsis in patients. The aim is to develop a point of care rapid diagnostic that can detect the genetic bio-makers of sepsis early and avoid deaths.
This product can also be utilised to identify a panel of specific immunological mediators involved in the facilitation of a cytokine storm when it presents in patients, as seen in COVID-19 and allow for a prompt diagnosis equipping clinicians with the right tools for early treatment.
This has the potential of saving many lives and saving the NHS millions of pounds.